Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Enovix Corporation (ENVX) Price & Performance

BioNano Genomics IncTrade
Enovix CorporationTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Enovix Corporation — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Enovix Corporation trades at $5.07 (market cap $1.10B). The key difference: Enovix Corporation is far larger — about 83.3× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.

BNGOENVX
Market Cap
$13.20M$1.10B
Sector
HealthTechnology
52-Week High
$4.92$15.93
52-Week Low
$1.09$4.84
Enterprise Value
$15.81M$1.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Enovix Corporation

ENVX trades at $4.95, down 4.81% with bearish technical signals despite recent earnings beats. The company shows negative profitability with -499.64% net margin and -$156.74M net loss for 2025, though revenue grew to $31.82M. Recent positive developments include the appointment of a former Apple operations leader as COO and progress in battery technology commercialization.

While analyst consensus remains bullish with a $12.75 price target, significant execution risks persist given negative cash flows and high valuation multiples. The stock presents high-risk speculation on Enovix's ability to scale production and achieve profitability in the competitive battery technology market.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Enovix Corporation

Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.

Read more on ENVX